Abstract
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that is usually caused by long-term exposure to harmful substances, such as cigarette smoke, which can lead to inflammation in the airways. Dupilumab is a drug that works by blocking the activity of interleukins 4 and 13, and helping to reduce type 2 inflammation in various organs, such as the lungs, sinuses, and skin. This summary of research provides an overview of the previously published article on the results of two phase 3 studies of patients with COPD and type 2 inflammation who were treated with either dupilumab or placebo for up to 52 weeks. Dupilumab reduced exacerbations and symptom severity, improved lung function and quality of life in these patients, and was well tolerated. These studies provide evidence that dupilumab is a safe and effective treatment option for patients with COPD who also show signs of type 2 inflammation. ClinicalTrials.gov Identifiers: BOREAS: NCT03930732; NOTUS: NCT04456673.
Keywords: Biologic, COPD, Dupilumab, Efficacy, Exacerbation, Lung function, Quality of life, Safety
Summary of Research
This is a summary of the original article “Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials” (Fig. 1) [1].
Fig. 1.
Summary of the clinical study and key findings
Acknowledgements
The authors would like to thank Elizabeth Laws, Jennifer Maloney, Xin Lu, and Deborah Bauer for their contributions to the original study, particularly for statistical analysis and performing statistical quality control of this research summary to ensure the accuracy of the data presented.
Medical Writing/Editorial Assistance
Medical writing support, under the direction of the authors, was provided by Martina Fuchsberger, PhD, employee of the Publications and Medical Affairs Division of Omnicom Health Medical Communications, funded by Sanofi and Regeneron Pharmaceuticals Inc., in accordance with the Good Publication Practice (GPP 2022) guidelines.
Author Contributions
Surya P. Bhatt, Klaus F. Rabe, Nicola A. Hanania, Claus F. Vogelmeier, Mona Bafadhel, Stephanie A. Christenson, Alberto Papi, Dave Singh, Linda Walsh, Tonya Winders, Ashish Bansal and Lacey B. Robinson contributed to the writing of this research summary and had full access to all data in the analysis, interpreted data, reviewed and edited the manuscript, and had final responsibility for the decision to submit for publication.
Funding
The research and Rapid Service Fee for this article was funded by Sanofi and Regeneron Pharmaceuticals Inc.
Declarations
Conflict of Interest
Please see the original article for full author disclosures. Linda Walsh and Tonya Winders have nothing to disclose.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material
Not applicable.
Reference
- 1.Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025;13(3):234–43. 10.1016/S2213-2600(24)00409-0. [DOI] [PubMed] [Google Scholar]